

# Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

#### 1.1. Product identifier

Product Name Pfizer-BioNTech COVID-19 Vaccine

Product Code(s) PF00092

**Synonyms** PF-07302048 containing PF-07305885 (BNT162b2); CorVAC Containing PF-07305885

(BNT162b2); CoVVAC Containing PF-07305885 (BNT162b2); COVID Vaccine Containing

PF-07305885 (BNT162b2); COVID-19 Vaccine Containing PF-07305885 (BNT162b2)

Trade Name: Not applicable Compound Number PF-07302048

Item Code H000022941: H000023057

Chemical Family: Lipid Nanoparticles containing PF-07305885 (BNT162b2) and Lipids

#### 1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product

### 1.3. Details of the supplier of the safety data sheet

Pfizer Inc
235 East 42nd Street
Ramsgate Road
New York, New York 10017
Sandwich, Kent
1-800-879-3477
CT13 9NJ
United Kingdom

+00 44 (0)1304 616161

#### 1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

E-mail address pfizer-MSDS@pfizer.com

## Section 2: HAZARDS IDENTIFICATION

#### 2.1. Classification of the substance or mixture

Not classified as hazardous

2.2. Label elements

Signal word Not classified

Hazard statements Not classified in accordance with international standards for workplace safety.

2.3. Other hazards

Other hazards An Occupational Exposure Value has been established for one or more of the ingredients

(see Section 8).

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 16-Nov-2020

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Page 2/10

Version 1.02

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

#### 3.1 Substances

NonHazardous

Chemical Name	EC No	CAS No	Weight-%	Classification according to Regulation (EC) No. 1272/2008 [CLP]	REACH Registration Number
Water	231-791-2	7732-18-5	*	Not Listed	
Sucrose	200-334-9	57-50-1	< 10	Not Listed	
SODIUM CHLORIDE	231-598-3	7647-14-5	< 10	Not Listed	
ALC-0315	Not Listed	NOT ASSIGNED	< 2	Not Listed	
Potassium phosphate	231-913-4	7778-77-0	< 1	Not Listed	
POTASSIUM CHLORIDE	231-211-8	7447-40-7	<1	Not Listed	
PF-07305885	Not Listed	NOT ASSIGNED	<1	Not Listed	
PF-07302048	Not Listed	NOT ASSIGNED	< 1	Not Listed	
PEGA / ALC-0159	Not Listed	NOT ASSIGNED	<1	Not Listed	
Disodium phosphate dihydrate	Not Listed	10028-24-7	< 1	Not Listed	
Cholesterol	200-353-2	57-88-5	< 1	Not Listed	
1,2-Distearoyl-sn-glycero-3 -phosphocholine	212-440-2	816-94-4	< 1	Not Listed	

#### Full text of H- and EUH-phrases: see section 16

**Additional information** 

\* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safetv.

#### Section 4: FIRST AID MEASURES

#### 4.1. Description of first aid measures

**Inhalation** Remove to fresh air. Seek immediate medical attention/advice.

**Eye contact** Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.

Consult a physician.

**Skin contact** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

**Ingestion** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do

not induce vomiting unless directed by medical personnel. Seek medical attention

immediately.

## 4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and No data available

\_\_\_\_\_

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 16-Nov-2020

effects

#### 4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

#### Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

**Suitable Extinguishing Media** Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the

Fine particles (such as mists) may fuel fires/explosions.

chemical

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

5.3. Advice for firefighters

Special protective equipment for fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout

Page 3 / 10

Version 1.02

gear. Use personal protection equipment.

#### Section 6: ACCIDENTAL RELEASE MEASURES

#### 6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

6.2. Environmental precautions

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be

taken to avoid environmental release.

#### 6.3. Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean

spill area thoroughly.

**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

### Section 7: HANDLING AND STORAGE

#### 7.1. Precautions for safe handling

#### Advice on safe handling

Restrict access to work area. No open handling permitted. Minimize generating airborne mists and vapors. If solvent based liquid, ground and bond all bulk transfer equipment. Use appropriate engineering controls to maintain exposures below the B-OEB taking all applicable routes of exposure into consideration. A change area to facilitate 'good laboratory/manufacturing' decontamination practices is recommended. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere

Revision date 16-Nov-2020 Version 1.02

should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store at < -70 °C in properly labeled containers. Keep away from heat, sparks, and flames.

7.3. Specific end use(s)

Specific use(s) Vaccine.

Product Name Pfizer-BioNTech COVID-19 Vaccine

#### Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

#### 8.1. Control parameters

#### **Exposure Limits**

Refer to available public information for specific member state Occupational Exposure Limits.

Sucrose

 ACGIH TLV
 10 mg/m³

 Bulgaria
 10.0 mg/m³

 Estonia
 10 mg/m³

 France
 10 mg/m³

 Ireland
 10 mg/m³

 STEL: 20 mg/m³

 Latvia
 5 mg/m³

 Lativia
 5 mg/m³

 Spain
 10 mg/m³

 OSHA PEL
 15 mg/m³

 5 mg/m³
 5 mg/m³

(vacated) TWA: 15 mg/m³ total dust (vacated) TWA: 5 mg/m³ respirable fraction Page 4/10

United Kingdom TWA: 10 mg/m³ STEL: 20 mg/m³

**SODIUM CHLORIDE** 

Latvia 5 mg/m³
Russia MAC: 5 mg/m³

Potassium phosphate

Russia MAC: 10 mg/m<sup>3</sup>

POTASSIUM CHLORIDE

Bulgaria5.0 mg/m³Latvia5 mg/m³RussiaMAC: 5 mg/m³

Pfizer OEB Statement: The Biotherapeutic Occupational Exposure Band (B-OEB) is an acceptable daily intake

(ADI) range, based on available hazard data with appropriate safety factors applied. Engineering control measures should be utilized to bring exposures into the relevant B-OEB; supplementary administrative controls and personal protective equipment are to be

used to achieve exposure control to the bottom of the band.

**SODIUM CHLORIDE** 

Pfizer Occupational Exposure OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Band (OEB):

**POTASSIUM CHLORIDE** 

Pfizer Occupational Exposure OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Band (OEB):

**PF-07305885**Pfizer Occupational Exposure

B-OEB Default (control exposure to the range of 10 μg/day to <100 μg/day)

Band (OEB):

PF-07302048
Pfizer Occupational Exposure

B-OEB 5 (control exposure to <10 µg/day)

Revision date 16-Nov-2020 Version 1.02

Band (OEB):

8.2. Exposure controls

Product Name Pfizer-BioNTech COVID-19 Vaccine

Engineering controls Engineering controls should be used as the primary means to control exposures. Use

process containment, local exhaust ventilation, biosafety cabinet, or other engineering controls to maintain airborne levels within the B-OEB range. It is recommended that all large scale operations should be fully enclosed. Air recirculation is not recommended.

Page 5/10

**Environmental exposure controls** No information available.

Personal protective equipment Contact your safety and health professional or safety equipment supplier for assistance in

selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the

selection and use of personal protective equipment (PPE).

**Eve/face protection** Wear safety glasses as minimum protection (goggles recommended). (Eye protection

must meet the standards in accordance with EN166, ANSI Z87.1 or international

equivalent.).

Hand protection Wear impervious disposable gloves (e.g. Nitrile, etc.) as minimum protection (double

recommended). (Protective gloves must meet the standards in accordance with EN374,

ASTM F1001 or international equivalent.).

**Skin and body protection**Wear impervious disposable protective clothing when handling this compound. Full body

protection is recommended (scale dependent). Wear impervious protective clothing when handling this compound. (Protective clothing must meet the standards in accordance with

EN13982, ANSI 103 or international equivalent.).

Respiratory protection

Under normal conditions of use, if the applicable Biotherapeutic Occupational Exposure

Band (B-OEB) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the B-OEB (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM

F2704-10 or international equivalent.).

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state
Color
Molecular formula (MF):
Molecular weight
Mixture
Mixture

Odor No data available.
Odor threshold No data available

Property Values 7.4

Melting point / freezing pointNo data availableBoiling point / boiling rangeNo data availableFlash pointNo data availableEvaporation rateNo data availableFlammability (solid, gas)No data available

Flammability Limit in Air

Upper flammability limit: No data available

Lower flammability limit: No data available

Product Name Pfizer-BioNTech COVID-19 Vaccine Page 6 / 10
Revision date 16-Nov-2020 Version 1.02

No data available Vapor pressure No data available Vapor density Relative density No data available Water solubility No data available Solubility(ies) No data available **Autoignition temperature** No data available No data available **Decomposition temperature** No data available Kinematic viscosity Dynamic viscosity No data available No data available **Explosive properties** No data available **Oxidizing properties** 

9.2. Other information

Liquid Density

No data available
Bulk density

No data available

## Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

**Reactivity** No data available.

10.2. Chemical stability

**Stability** Stable under normal conditions.

**Explosion data** 

Sensitivity to Mechanical Impact No data available. Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep

away from heat sources and electrostatic discharge.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

## Section 11: TOXICOLOGICAL INFORMATION

#### 11.1. Information on toxicological effects

**General Information:** Toxicological properties have not been thoroughly investigated. The following information is

available for the individual ingredients.

Known Clinical Effects: Based on clinical trials in humans, possible adverse effects following intravenous exposure

to this compound may include: muscle pain, abnormal redness of skin (erythema), fever,

and sleep disturbances.

Acute Toxicity: (Species, Route, End Point, Dose)

Sucrose

Rat Oral LD 50 29,700 mg/kg

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m<sup>3</sup>

Rat Oral LD 50 3 g/kg

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 16-Nov-2020

Mouse Oral LD 50 4 g/kg Rabbit Dermal LD 50 > 10 g/kg

POTASSIUM CHLORIDE

Rat Oral LD50 2600 mg/kg

Potassium phosphate

Rat Oral LD50 3200 mg/kg

Rabbit Dermal LC50 > 4640 mg/kg

Chemical Name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg ( Rat )	-	-
Sucrose	= 29700 mg/kg (Rat)	-	-
SODIUM CHLORIDE	= 3 g/kg (Rat)	-	> 42 g/m³(Rat)1 h
Potassium phosphate	= 3200 mg/kg (Rat)	-	-
POTASSIUM CHLORIDE	= 2600 mg/kg (Rat)	-	-

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE
Skin Irritation Rabbit Mild
Eye Irritation Rabbit Mild
POTASSIUM CHLORIDE

Eye Irritation Rabbit Mild

## Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ) PF-07302048

4 Week(s) Rat Intramuscular \*10 μg LOAEL Skin, Blood forming organs, Blood, Skeletal muscle, Lymphoid tissue, Spleen **Repeated Dose Toxicity Comments: PF-07302048:** \* Doses were administered once a week.

## Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s)) Potassium phosphate

Reproductive & Fertility Rat No route specified 282 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus Reproductive & Fertility Mouse No route specified 320 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Potassium phosphate

Bacterial Mutagenicity (Ames) Salmonella Negative

Carcinogenicity See below

Cholesterol

IARC Group 3 (Not Classifiable)

#### Section 12: ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should

be avoided.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

POTASSIUM CHLORIDE

Gambusia affinis (Mosquitofish) LC50 96 hours 920 mg/l

PF00092

Page 7 / 10 Version 1.02

Page 8/10

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 16-Nov-2020

Revision date 16-Nov-2020 Version 1.02

Lepomis macrochirus (Bluegill Sunfish) LC50 96 hours 2010 mg/L Daphnia Magna (Water Flea) EC50 48 hours 825 mg/l Scenedesmus subspicatus (Green Alga) EC50 72 Hours 2500 mg/L

#### 12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

**Bioaccumulation** No information available.

12.4. Mobility in soil

Mobility in soil No information available.

#### 12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment No information available.

Chemical Name	PBT and vPvB assessment	
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does	
	not apply	
Potassium phosphate	The substance is not PBT / vPvB PBT assessment does	
	not apply	
POTASSIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does	
	not apply	
Cholesterol	The substance is not PBT / vPvB	

#### 12.6. Other adverse effects

Other adverse effects No information available.

## Section 13: DISPOSAL CONSIDERATIONS

#### 13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

#### Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## Section 15: REGULATORY INFORMATION

## 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

W.	
Water CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Sucrose	Not Listed Not Listed Present 231-791-2 Present
CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS	Not Listed Not Listed Present 200-334-9 Present
SODIUM CHLORIDE CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS	Not Listed Not Listed Present 231-598-3 Present
ALC-0315 CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS Potassium phosphate	Not Listed Not Listed Not Listed
CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS POTASSIUM CHLORIDE	Not Listed Not Listed Present 231-913-4 Present
CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Standard for Uniform Scheduling of Medicines and	Not Listed Not Listed Present 231-211-8 Present Schedule 4
Poisons (SUSMP) PF-07305885 CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS PF-07302048	Not Listed Not Listed Not Listed
CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS PEGA / ALC-0159	Not Listed Not Listed Not Listed
CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS Disodium phosphate dihydrate	Not Listed Not Listed Not Listed
CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS AICS	Not Listed Not Listed Not Listed Present
Standard for Uniform Scheduling of Medicines and	Schedule 5

Page 10 / 10

Revision date 16-Nov-2020 Version 1.02

Poisons (SUSMP)

Cholesterol

CERCLA/SARA Section 313 de minimus % Not Listed
California Proposition 65 Not Listed
TSCA Present
EINECS 200-353-2
AICS Present
Standard for Uniform Scheduling of Medicines and Schedule 4

Poisons (SUSMP)

1,2-Distearoyl-sn-glycero-3-phosphocholine

Product Name Pfizer-BioNTech COVID-19 Vaccine

CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed EINECS 212-440-2

15.2. Chemical safety assessment

Chemical Safety Report No information available

#### Section 16: OTHER INFORMATION

#### Key or legend to abbreviations and acronyms used in the safety data sheet

**Data Sources:** Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the

Company/Undertaking.

Revision date 16-Nov-2020

Prepared By Product Stewardship Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.